In this systematic review and network meta-analysis, PCSK9 inhibitors, as adjuvant treatment in statin-treated hypercholesterolemia patients, were associated with greater reduction in atherogenic lipid level, including LDL-C, ApoB, and Lp(a). Here, PCSK9 is linked to familial hypercholesterolemia.